1599. Real-World Efficacy of Long-Acting Cabotegravir and Rilpivirine in an Urban HIV Clinic

BACKGROUND: Long-Acting cabotegravir/rilpivirine (LA-CAB/RPV) is the first FDA-approved, complete, long-acting injectable antiretroviral therapy (ART) regimen. In clinical trials, LA-CAB/RPV has proven to be highly effective in maintaining virologic suppression in people living with HIV (PLWH) with...

Descripción completa

Detalles Bibliográficos
Autores principales: Perez, Sarah, Petersen, Elizabeth, Huhn, Gregory
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677117/
http://dx.doi.org/10.1093/ofid/ofad500.1434

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677117/
http://dx.doi.org/10.1093/ofid/ofad500.1434

Ejemplares similares